Ozempic and Mounjaro have been making waves as effective weight loss solutions for people with obesity and type 2 diabetes.
But according to a newly published study in JAMA Network Open, their benefits may extend far beyond the bathroom scale.
Belonging to a class of drugs called GLP-1 receptor agonists, these medications were initially developed to regulate blood sugar.
Later, they gained approval for helping with weight management.
But now, researchers believe that these drugs could be doing much more – including lowering the risk of several serious health conditions.
What’s truly eye-opening is that these potential benefits might not be directly tied to weight loss itself.
Scientists have observed that some of the positive effects, like heart protection and reduced inflammation, occur even before significant weight loss begins.
So what else might these medications be influencing?
A protective shield against cancer?
Involving more than 1.6 million people with type 2 diabetes, the study compared patients prescribed GLP-1 drugs to those taking insulin.
The results were striking: those on GLP-1 medications had significantly lower risks for ten different types of cancer – including pancreatic, liver, colorectal, and ovarian cancer.
To put it into numbers: a 65 % lower risk of gallbladder cancer, 59 % less risk of pancreatic cancer, and around 40-50 % reductions in several others.
That’s more than a side effect – it’s a potential health revolution.
While the exact cause is still under investigation, researchers suggest several possible explanations.
These drugs may help reduce chronic inflammation, improve insulin resistance, and even encourage better eating habits – factors that could all contribute to lower cancer risk.
A cautious optimism for the future
Despite the promising results, experts are quick to emphasize caution.
The study relied on prescription data and didn’t track whether patients actually took the medication or lost weight.
And because many patients were also taking other drugs like metformin, it’s hard to isolate the specific impact of GLP-1s.
Still, researchers agree on one thing: the findings are encouraging. As more people use these medications for obesity rather than diabetes alone, we may see even clearer results.
Until then, doctors advise patients and clinicians to keep the potential cancer protection in mind when considering treatment options.
In a field where breakthroughs are rare, Ozempic and Mounjaro might just be the beginning of a much bigger shift in how we treat chronic diseases.
This article is based on information from National Geographic.